Clinical Trial Update: Study Investigating a PEGylated Recombinant Factor VIII (BAX 855) for Hemophilia A (PROLONG-ATE Study) [Phase 2, Phase 3]

View source ↗

Summary

Study update on PEGylated recombinant Factor VIII (BAX 855) for Hemophilia A completed with posted results.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hemophilia

Drugs mentioned

• BAX 855

Snippet

Sponsor: Baxalta now part of Shire | Conditions: Hemophilia A | Phase 2, Phase 3 | Status: COMPLETED | Results posted: 2016-09-07